Putting the Guidelines into Practice: Building a State-of-the-Art Lipid and Cardiometabolic Clinic-Panel Discussion With Audience Question and Answers

Video Transcription

Video Summary

The session transitions to a Q&A on cardiometabolic team care and lipid management. Panelists emphasize pharmacists’ value in complex medication titration (e.g., GLP-1s, hypertension, diabetes) and cost navigation, though billing and scope vary by state; partnering with pharmacy schools can reduce cost. On LDL lowering, the panel agrees there’s no evidence of a “too low” LDL threshold, citing PCSK9 trials with very low achieved LDL and no excess adverse effects. Addressing socioeconomic barriers, speakers note low-cost generics (statins, ezetimibe), discount pharmacies, and nonpharmacologic supports (community health workers, case managers). GLP-1 receptor agonists are highlighted as high-impact—especially in advanced CKM—while others stress stage-based care and lifestyle first. Risk enhancers are framed as decision aids in borderline-risk patients and, in CKM staging, as predictors of disease progression. Questions cover elevated lipoprotein(a) in young patients: management depends on level, family history, shared decision-making, cascade screening, and trial referral. Building lipid clinics may rely on quality metrics and system-wide value rather than RVUs.

Keywords

cardiometabolic team-based care

lipid management and LDL lowering

PCSK9 inhibitors and very low LDL safety

pharmacist-led medication titration and cost navigation

GLP-1 receptor agonists in CKM staging

lipoprotein(a) management and cascade screening